Biotech Values

[dewophile]

CEO Dan Browne said on a recent webcast that a larger proportion of SAKURA-3 patients than originally expected opted to be treated with RT002 a second time

That's certainly good news. I always felt that a good safety profile would be the base case in this trial but perhaps other data like pt satisfaction etc. (and more confirmation on extended duration) could end up as a nice added plus